In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
about
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSmall and Innovative Molecules as New Strategy to Revert MDRChemoresistance and targeted therapies in ovarian and endometrial cancersA new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosisGenetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoniPrediction of promiscuous p-glycoprotein inhibition using a novel machine learning schemeInhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to PraziquantelRole of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosinA selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Rapid detection of ABC transporter interaction: potential utility in pharmacology.Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress.The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cellsIdentification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upSelective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.Improving cancer chemotherapy with modulators of ABC drug transporters.Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazineBiodegradable mixed MPEG-SS-2SA/TPGS micelles for triggered intracellular release of paclitaxel and reversing multidrug resistance.Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.Zuo Jin Wan, a Traditional Chinese Herbal Formula, Reverses P-gp-Mediated MDR In Vitro and In VivoA pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PETSynthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
P2860
Q21246014-40F386E4-5561-4B8F-9EA4-A73B8F808874Q24644255-FF567C9C-810D-481A-BEEA-194ACAE737DEQ27012455-271C7675-483D-4D54-B5D9-DC51339F479BQ28073246-9C3695A8-A72A-4DFF-9C2E-2D2A95C32468Q28476087-7F164F65-DB8E-46FF-86A4-4796321C00FFQ28478288-545256D6-683D-4054-9F3F-DCA480938AAAQ28481547-FD912B37-3471-448C-9659-2B6226E238E8Q28543846-841F50F8-26EF-4A6D-8842-764DE61E9C01Q30274798-539E7767-BB7B-4CEA-A281-CE4AE3465D74Q33394070-DE5DCF91-8AA2-479F-BC7D-D3476CEA76F6Q33490314-5E4CC3B9-D007-463A-98B8-A82AB02B4120Q33633267-6F1C8477-A5FE-4853-A979-38A2C8C8EA43Q33651025-83591953-F98C-48C2-A715-F7EC664900D1Q33776536-52DEE383-65ED-42D7-A507-568BC59583EFQ33991690-0B87D8CF-590A-4207-B8E9-40629845C5D0Q34005841-1610A812-D778-442F-98BE-AE4D0B9605C6Q34393952-899E9EB8-6BF0-4C5D-80EE-BF1E67F3CBD1Q34581006-61019F1A-A23C-47F2-820F-23B946BCFDBBQ34743441-90020820-5EED-45EB-BE56-1F756A71AAD7Q34768677-DAE8871D-E1B7-4CDD-A016-DED6E855A5A4Q34913068-1E585126-8DF6-4371-A2B8-C8F50E6C57F5Q35209207-7E9AF1DD-D3E2-4C1D-B0AB-9E2602720326Q35267029-DB350EB3-7A34-4E6D-81AF-ECA51EE3EA52Q35644350-ADBAD29E-301F-4712-B648-578C8DA640DCQ35720625-C9F2E3DC-BCCE-41D8-9F32-75E06ACD916DQ35845827-7B0C5888-3DBE-464B-AA28-A0D5F54A3910Q36057369-D533DC01-9393-4379-95AA-6B568646D6F5Q36088140-945CF125-914F-407F-8277-37984F52D4ADQ36108251-FCE3D961-B835-4EEE-9FAF-933065E0CAC0Q36161579-F13E4667-F937-41F1-A1AD-6842B0712B97Q36175486-F6CFF94F-D9B6-46B4-954E-9F5AC757BE4CQ36355661-D3C5D8AE-2938-41B0-9FDB-3996648F5544Q36413392-24417C2E-FF88-429F-A175-AFB62A8F4AFEQ36571957-A9C4B513-730E-4B91-817C-B58AC3BA317CQ36702964-6E0E76CD-1D81-40A0-A250-43EBAFD6D980Q36949068-62D8666C-425E-4061-88DD-4903FED549EEQ36949086-3475872C-1D5A-4F73-834A-18DB076F083BQ36949854-76BF1D96-ABA6-492A-8DDC-C6B01C157937Q37010772-8A5A69E5-E359-4419-BF8E-E37672390EF8Q37281354-77E80ED3-EAA2-432D-AD8F-453DB783A1BB
P2860
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@ast
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@en
type
label
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@ast
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@en
prefLabel
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@ast
In vitro and in vivo reversal ...... ovel potent modulator, XR9576.
@en
P2093
P1433
P1476
In vitro and in vivo reversal ...... novel potent modulator, XR9576
@en
P2093
A J Stewart
D Templeton
P Charlton
W Dangerfield
P304
P407
P577
2001-01-01T00:00:00Z